New program management deal for Clinigen Group

STAFFORDSHIRE pharmaceutical group Clinigen has secured a further program management deal for its Clinigen Global Access Programs.

The program will provide access to Raptor Pharmaceuticals Corp’s PROCYSBI® (cysteamine bitartrate) for individual patients with nephropathic cystinosis.

Through the program PROCYSBI® will be available worldwide, except for the United States where the drug is already commercially available, Latin America and a small number of European territories.

Nephropathic cystinosis is a rare, inherited condition caused by a build up of cystine that affects every cell in the body. Without treatment, patients can suffer from kidney and eye problems and eventually severe and irreversible damage to the heart, central nervous system and muscles. Approximately 2,000 people worldwide are currently diagnosed with the disorder1.

PROCYSBI® is a delayed-release form of cysteamine bitartrate that can be used to manage cystinosis by continually reducing the toxic levels of cystine in the cells. This can help to prevent cellular damage and delay the progression of cystinosis and its complications.

Mark Corbett, Senior Vice President, Clinigen GAP said: “Nephropathic cystinosis is a serious, progressive disease and the initiation of this program for PROCYSBI® is a key step in getting an important new therapeutic option to patients with limited treatment options.  

“We are very proud that Raptor have selected Clinigen GAP as their partner to manage this global access program. We are able to utilize our extensive international expertise in project management, regulatory advice and logistics in order to ensure Raptor can effectively address this area of unmet medical need.”

New NED for S&U

THE board of Solihull-based home credit and motor finance provider S&U has announced the appointment of Graham Pedersen as a new independent Non-Executive Director with immediate effect.

Anthony Coombs, chairman of S&U said: “We are very pleased that Graham has accepted our invitation to join the S&U board. Graham has enormous experience both as a regulator at the Prudential Regulation Authority and as a banker with detailed knowledge and involvement in the speciality finance sector, particularly in motor finance.

“As the group progresses its full authorisations in home credit and motor finance divisions with the Financial Conduct Authority this year, Graham’s expertise will be invaluable.”

Pedersen has also agreed to accept the chairmanship of the new board Compliance Committee and will give advice on corporate governance as well as sitting on the Nomination, Remuneration and Audit Committees.

bwin appoints HomeServe chair as new NED

THE chairman of Walsall-based home maintenance provider HomeServe, J M Barry Gibson has been appointed as a new independent Non-Executive Director for bwin.party digital entertainment plc. The appointment is effective from March 1.

Gibson will become Senior Independent Director of bwin and will chair the Remuneration Committee.
 

New NED for Arden Partners

STOCKBROKER Arden Partners has announced the appointment of Luke Johnson as a Non-Executive Director.  The appointment will take effect on March 20, 2015 subject to regulatory approval.